1. Home
  2. Labeler Index
  3. Genentech, Inc.
  4. 50242-088
  5. NDC Package Code: 50242-088-01 Kadcyla

NDC Package 50242-088-01 Kadcyla

Ado-trastuzumab Emtansine Injection, Powder, Lyophilized, For Solution Intravenous - View Billable Units, 11-Digit Format, RxNorm

Table of Contents

    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Frequently Asked Questions

Package Information

Find all the important details about this NDC Package code, including the 11-Digit NDC Billing number, billing units, wholesale price, RxNorm crosswalk, active ingredients, pharmacologic clasess, etc.

NDC Package Code:
50242-088-01
Package Description:
1 VIAL, SINGLE-USE in 1 CARTON / 5 mL in 1 VIAL, SINGLE-USE
Product Code:
50242-088
Proprietary Name:
Kadcyla
Non-Proprietary Name:
Ado-trastuzumab Emtansine
Substance Name:
Trastuzumab Emtansine
Usage Information:
Trastuzumab emtansine is used to treat certain types of breast cancer. This medication is used to treat tumors that produce more than the normal amount of a certain substance called HER2 protein. This medication is called a monoclonal antibody and microtubule inhibitor conjugate. Trastuzumab emtansine works by attaching to the HER2 cancer cells and blocking them from dividing and growing. It may also destroy the cancer cells or signal the body (immune system) to destroy the cancer cells. This monograph is about the following trastuzumab emtansine products: trastuzumab emtansine, ado-trastuzumab emtansine.
11-Digit NDC Billing Format:
50242008801
Billing Unit:
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
NDC to RxNorm Crosswalk:
1 EA
NDC to RxNorm Crosswalk:
  • RxCUI: 1658084 - ado-trastuzumab emtansine 100 MG Injection
  • RxCUI: 1658087 - KADCYLA 100 MG Injection
  • RxCUI: 1658087 - ado-trastuzumab emtansine 100 MG Injection [KADCYLA]
  • RxCUI: 1658089 - ado-trastuzumab emtansine 160 MG Injection
  • RxCUI: 1658091 - KADCYLA 160 MG Injection
    • Product Type:
    Human Prescription Drug
    Labeler Name:
    Genentech, Inc.
    Dosage Form:
    Injection, Powder, Lyophilized, For Solution - A dosage form intended for the solution prepared by lyophilization ("freeze drying"), a process which involves the removal of water from products in the frozen state at extremely low pressures; this is intended for subsequent addition of liquid to create a solution that conforms in all respects to the requirements for Injections.
    Administration Route(s):
  • Intravenous - Administration within or into a vein or veins.
    • Active Ingredient(s):
  • TRASTUZUMAB EMTANSINE 20 mg/mL
    • Sample Package:
    No
    FDA Application Number:
    BLA125427
    Marketing Category:
    BLA - A product marketed under an approved Biologic License Application.
    Start Marketing Date:
    02-22-2013
    Listing Expiration Date:
    12-31-2024
    Exclude Flag:
    N
    Code Structure:

    The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

    * Please review the disclaimer below.

    NDC HCPCS Crosswalk

    This crosswalk is intended to help the public understand which drug products (identified by NDCs) are assigned to which HCPCS billing codes.

    NDC 50242-088-01 HCPCS crosswalk information with package details and bill units information.

    NDC Billing CodeHCPCS CodeHCPCS Code Desc.DosagePackage SizePackage QuantityBillable UnitsBillable Units / Pkg
    50242008801J9354Inj, ado-trastuzumab emt 1mg1 MG11100100

    * Please review the disclaimer below.

    Frequently Asked Questions

    What is NDC 50242-088-01?

    The NDC Packaged Code 50242-088-01 is assigned to a package of 1 vial, single-use in 1 carton / 5 ml in 1 vial, single-use of Kadcyla, a human prescription drug labeled by Genentech, Inc.. The product's dosage form is injection, powder, lyophilized, for solution and is administered via intravenous form.This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package.

    Is NDC 50242-088 included in the NDC Directory?

    Yes, Kadcyla with product code 50242-088 is active and included in the NDC Directory. The product was first marketed by Genentech, Inc. on February 22, 2013 and its listing in the NDC Directory is set to expire on December 31, 2024 if the product is not updated or renewed by the manufacturer.

    What is the NDC billing unit for package 50242-088-01?

    The contents of this package are billed per "each", products billed on a per each basis are usually products dispensed in discreet units. The calculated billable units for this package is 1.

    What is the 11-digit format for NDC 50242-088-01?

    The 11-digit format is 50242008801. The 11-digit billing format might be required by the Centers for Medicare & Medicaid Services (CMS) and other payers in billing claim forms.

    This package code is originally configured in a 5-3-2 segment 10-digit format and by adding a zero within the original NDC package code we can obtain the converted 11-digit format in a 5-4-2 segment configuration. The table below shows the 11-digit code conversion:

    10-Digit Format10-Digit Original Code11-Digit Format11-Digit Code
    5-3-250242-088-015-4-250242-0088-01